What it is
KPV is the Lys-Pro-Val C-terminal tripeptide associated with α-MSH research. It is not a substitute for an approved medicine.
Mechanism and research questions
- Research has examined melanocortin-related signaling and effects that may occur independently of MC1R.
- Intestinal transport and PepT1-mediated uptake have been investigated in epithelial and immune-cell models.
Human evidence
No robust human efficacy or safety program was identified in the sources reviewed for this profile.
Preclinical / mechanistic evidence
Mouse and cellular studies report anti-inflammatory signals; these findings do not establish clinical benefit.
Evidence summary
The strongest directly located evidence is preclinical, including murine colitis and inflammation models.
Limits and interpretation
- Animal and in-vitro findings may not translate to humans.
- No validated clinical dosing or treatment protocol is provided here.
- Commercial-vial identity, purity, and stability require batch-specific documentation.
Regulatory and identity note
Not presented as an approved therapeutic in this catalog; research-use identity only.